viewSareum Holdings PLC

Sareum receives worldwide rights to FLT3 programme

FLT3 is investigating kinase inhibitors, which are designed to reduce immune system overreaction to viral infections such as coronavirus (COVID-19)

Sareum Holdings PLC - Sareum receives worldwide rights to FLT3 programme

Sareum Holdings PLC (LON:SAR) said it has received the worldwide rights to the FLT3+Aurora kinase inhibitor programme which is designed to help treat immune system overreaction to coronavirus (COVID-19) and other viral infections.

In an announcement late on Friday afternoon, the AIM-listed drug development firm said its licensing partner for FLT3 has decided not to exercise its option to continue the development of the programme, and as a result rights to the programme will now revert to Sareum.

The company said FLT3 was licensed to a China-based speciality pharma company in March 2020, for which Sareum received an upfront payment of £50,000.

READ: Sareum Holdings formally receives US patent protection for its pre-clinical cancer programme

Sareum said while the licensee had improved the bioavailability of the lead compound in the FLT3 programme, it has been unable to achieve the level needed to trigger the milestone under the licensing agreement and, as a result, it has decided to terminate the licence agreement and relinquish its rights to the FLT3 programme, with no further payments being due to Sareum.

"We will review the data and progress made with the programme by our Chinese partner over the coming weeks and will evaluate options for re-partnering the FLT3 programme. While early studies with our FLT3+Aurora kinase inhibitors were promising, formulation continues to be a challenge”, Sareum chief executive Tim Mitchell said in a statement.

“Our clear priority focus remains on advancing our proprietary TYK2/JAK1 programmes and, in the near-term, on completing the preclinical work needed for the first Clinical Trial Application during the first quarter of the year. Achieving this important milestone will be a key step in generating shareholder value from our TYK2/JAK1 pipeline", he added.

Shares in the company surged 20% to 2.1p in early deals on Monday.

Quick facts: Sareum Holdings PLC

Price: 1.725 GBX

Market: AIM
Market Cap: £56.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...


Market Report: Washington riots and Trump Twitter suspension drag down FTSE...

The Market Report with Katie Pilbeam. FTSE 100 has lost a little momentum this morning after reaching its highest level since early March on Wednesday.  Facebook and Twitter have blocked Donald Trump from their platforms after supporters swarmed the Capitol building on Wednesday. The US...

on 7/1/21

2 min read